Descrizione del progetto
Una svolta per l’uso delle ciclodestrine in campo farmaceutico
Le ciclodestrine sono un eccipiente promettente per l’uso in formulazioni di farmaci e vaccini, che di recente ha raccolto un’attenzione significativa da parte dell’industria farmaceutica. Questo eccipiente sta attraversando una fase di sostanziale innovazione, con l’introduzione di nuovi sistemi basati su ciclodestrine e applicazioni terapeutiche. Purtroppo, gli errori di comunicazione e le incomprensioni tra le industrie private e il mondo accademico hanno ostacolato il progresso dell’utilizzo delle ciclodestrine. Il progetto Bicyclos, finanziato dall’UE, intende affrontare queste sfide riunendo un team di specialisti ed esperti che formeranno nuovi ricercatori e condurranno ricerche su nuove applicazioni e sviluppi delle ciclodestrine. In definitiva, il progetto collaborerà con un consorzio di 11 partner per migliorare l’introduzione e la diffusione dell’uso delle ciclodestrine.
Obiettivo
Cyclodextrins (CD) have already gained several market applications as excipients in drug and vaccine formulations. They are very appealing platforms for the development of therapeutic applications and new CD-based systems are continuously proposed. In this frame easily prepared CD polymers frequently outstand the performance of the corresponding CD monomers. Nevertheless, application of new CDs as drug or delivery system in the clinics does not take off in spite of their most promising features. This is mainly due to a lack in transfer of knowledge between the academic world and the private sector focusing on CD for biomedical applications. The consortium formed by a multidisciplinary team, all with interest in CD and nanomedicines, accepts the challenge to bring CD-based systems closer to clinical application. To reach this goal an intense secondment scheme for young and experienced researchers is envisaged with activities that are all contributing to the scientific pursuit of CD progress. Activities focus on the design of sustainable syntheses of new CD, full characterization of new functionalized CD, the preparation of CD delivery systems for therapeutics and the study of the biological behavior of the CD-based nanomedicines in 2D and 3D models. The teams will embrace, already from the design stage, the production standards affording compliance with GMP for medicine development and prefer strategic approaches in line with the EU 2030 Agenda for Sustainable Development. The consortium features 11 partners with 4 coming from the private sector. Two of them hold concrete interest in the exploitation of research results as their core business focuses on CD for biomedical applications. This intersectoral and interdisciplinary team will foster new applications of CD-based systems as drugs, delivery systems or sensors and participating staff will enrich their profile with scientific and soft skills that are easily transferred to other research topics or sectors.
Campo scientifico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural scienceschemical sciencespolymer sciences
- medical and health sciencesmedical biotechnologynanomedicine
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors
Programma(i)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Meccanismo di finanziamento
HORIZON-TMA-MSCA-SE - HORIZON TMA MSCA Staff ExchangesCoordinatore
00185 Roma
Italia